Molecular signatures of intrahepatic cholangiocarcinoma: role in targeted therapy selection

被引：0
|
作者：
Glushko, Tetiana [1 ]
Costello, James [1 ]
Chima, Ranjit [1 ]
McGettigan, Melissa [1 ]
Kim, Richard [1 ]
Jeong, Daniel [1 ]
Qayyum, Aliya [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, 2902 USF Magnolia Dr, Tampa, FL 33612 USA
来源：
EUROPEAN JOURNAL OF RADIOLOGY | 2025年 / 187卷
关键词：
BILIARY-TRACT CANCER; MUTATIONS; CHEMOTHERAPY; ARID1A; MULTICENTER; EXPRESSION; PROGNOSIS; SURVIVAL; FEATURES; PATHWAY;
D O I：
10.1016/j.ejrad.2025.112056
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Cholangiocarcinoma is a highly lethal disease with a 5-year overall survival rate of 7-20%. A minority of patients present with resectable disease, and relapse rates remain high. Emerging data from next generation sequencing analysis have identified various actionable mutations which drive the different disease courses opening door to precision medicine and targeted therapies. This review focuses on the clinical significance of genetic alterations as well as the role of systemic therapies, immunotherapy and targeted therapies for intrahepatic cholangiocarcinoma.
引用
收藏
页数：28
相关论文
共 50 条
  • [41] Precision therapy for intrahepatic cholangiocarcinoma: A case report on adjuvant treatment in a recurrent patient after surgery and literature review
    Ying, Bao
    Tang, Tao
    Zhang, Li-Xing
    Xiong, Jian-Wei
    Zhao, Kai-Feng
    Li, Jia-Wei
    Wu, Guo
    ONCOLOGY LETTERS, 2024, 27 (02)
  • [42] Role of cancer stem cell heterogeneity in intrahepatic cholangiocarcinoma
    Zhang, Yiwang
    Xie, Juping
    Huang, Xiangqi
    Gao, Jintian
    Xiong, Zhiyong
    TRANSLATIONAL CANCER RESEARCH, 2025, 14 (02) : 1265 - 1281
  • [43] The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
    Fiste, Oraianthi
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Liontos, Michalis
    Koutsoukos, Konstantinos
    Dimopoulos, Meletios Athanasios
    Zagouri, Flora
    VACCINES, 2021, 9 (05)
  • [44] Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach
    Ahn, Keun Soo
    O'Brien, Daniel
    Kang, Yu Na
    Mounajjed, Taofic
    Kim, Yong Hoon
    Kim, Tae-Seok
    Kocher, Jean-Pierre A.
    Allotey, Loretta K.
    Borad, Mitesh J.
    Roberts, Lewis R.
    Kang, Koo Jeong
    HEPATOLOGY INTERNATIONAL, 2019, 13 (04) : 490 - 500
  • [45] Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
    Du, Jiajia
    Lv, Xing
    Zhang, Zunyi
    Huang, Zhiyong
    Zhang, Erlei
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [46] Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma
    Sur, Malini D.
    In, Haejin
    Sharpe, Susan M.
    Baker, Marshall S.
    Weichselbaum, Ralph R.
    Talamonti, Mark S.
    Posner, Mitchell C.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (07) : 2209 - 2217
  • [47] Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics
    Cui, Xiaowen
    Huang, Teng
    Jiang, Tianyi
    Wang, Hongyang
    CANCER LETTERS, 2025, 614
  • [48] Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
    Sia, D.
    Tovar, V.
    Moeini, A.
    Llovet, J. M.
    ONCOGENE, 2013, 32 (41) : 4861 - 4870
  • [49] Molecular Mechanisms of Tamoxifen Therapy for Cholangiocarcinoma: Role of Calmodulin
    Pawar, Pritish
    Ma, Liping
    Byon, Chang Hyun
    Liu, Hui
    Ahn, Eun-Young
    Jhala, Nirag
    Arnoletti, Juan P.
    McDonald, Jay M.
    Chen, Yabing
    CLINICAL CANCER RESEARCH, 2009, 15 (04) : 1288 - 1296
  • [50] Adjuvant Therapy for Intrahepatic Cholangiocarcinoma: The Debate Continues
    Zhu, Andrew X.
    Knox, Jennifer J.
    ONCOLOGIST, 2012, 17 (12) : 1504 - 1507
12345